FDA Raises Concerns About Patanase Inactive Ingredient
This article was originally published in The Pink Sheet Daily
Alcon is testing a modified formulation of the olopatadine nasal spray, which is awaiting approval for treatment of seasonal allergic rhinitis.
You may also be interested in...
Olopatadine reformulation will require additional preclinical testing, firm says.
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.